Efficacy of ketamine in the treatment of migraines and other unspecified primary headache disorders compared to placebo and other interventions: a systematic review.
Neysan ChahMike JonesSteve MilordKamal Al-EryaniReyes EncisoPublished in: Journal of dental anesthesia and pain medicine (2021)
Further double-blind controlled studies are needed to assess the efficacy of ketamine in treating acute and chronic refractory migraines and other primary headaches using intranasal and subcutaneous routes. These studies should include a long-term follow-up and different ketamine dosages in diagnosed patients following international standards for diagnosing headache/migraine.
Keyphrases
- double blind
- end stage renal disease
- pain management
- chronic kidney disease
- ejection fraction
- newly diagnosed
- liver failure
- prognostic factors
- placebo controlled
- physical activity
- clinical trial
- case control
- randomized controlled trial
- intensive care unit
- respiratory failure
- study protocol
- patient reported
- phase ii
- combination therapy
- open label